Boccioletti V

Cominacini L.

Cominacini M

Fratta Pasini A

Garbin U

Manfro S

Mozzini C

Pasini A

Stranieri C

Background This study was conducted to evaluate (i) the effect of nebivolol, a selective β1-adrenergic receptor antagonist, on plasma concentration of asymmetric dimethylarginine (ADMA) and on flow-mediated dilation (FMD) in essential hypertensive patients; (ii) the effect of serum derived from the treated hypertensive patients on ADMA and on dimethylarginine dimethylaminohydrolase 2 (DDAH2), the enzyme that selectively degrades ADMA, in human umbilical vein endothelial cells (HUVECs).  Methods Forty healthy subjects and 40 matched essential hypertensive patients treated with atenolol and nebivolol according to a double-blind, randomized design participated in the study. Evaluation of brachial artery (BA) reactivity was performed by a longitudinal B-mode scan of the right BA. ADMA and L-arginine were measured by high-performance liquid chromatography. DDAH2 expression and endothelial nitric oxide synthase activity (eNOS) were also evaluated in HUVECs.  Results ADMA levels were significantly decreased and FMD increased only in patients receiving nebivolol (P &lt; 0.01). Furthermore, in nebivolol group, we found a significant correlation between changes in ADMA levels and changes in FMD (P &lt; 0.01). Sera derived from patients treated with nebivolol but not with atenolol decreased ADMA and increased DDAH2 expression and eNOS activity (P &lt; 0.001) in HUVECs.  Conclusions The results of this study demonstrate that the improvement of endothelial dysfunction induced by nebivolol in hypertensive patients may be related to its effect on circulating ADMA levels. Although the mechanism by which nebivolol reduces circulating ADMA in hypertensive patients remains unclear, our ex vivo results suggest that the up-regulation of DDAH2 expression may have a role

FRATTA PASINI, Anna Maria

GARBIN, Ulisse

STRANIERI, Chiara

BOCCIOLETTI, Veronica

MOZZINI, Chiara

MANFRO, Stefania

PASINI, Andrea

COMINACINI, Luciano

Catalogo dei prodotti della ricerca

Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients

Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients

Abstract

Similar works

Full text

Available Versions

Catalogo dei prodotti della ricerca